Stifel expects Alnylam's heart disease drug to be 'go-to therapy'

Brokerage Stifel raises PT on drugmaker Alnylam Pharmaceuticals' ALNY.O to $345 from $300 following expanded U.S. approval for its heart disease drug

The new PT represents a 28.5% upside to the stock's last close

Brokerage believes ALNY's drug Amvuttra will be a "go-to therapy" for patients with heart disease condition who progress on a stabilizer

Amvuttra, a quarterly injection, was cleared to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart and potentially causing organ to fail

Stifel says physician feedback on the drug has been broadly favorable

Twenty four of 31 brokerages rate the stock "buy" or higher, 7 "hold"; their median PT is $316.71, according to data compiled by LSEG

As of last close, ALNY has risen 80% in past 12 months